Press Releases 2013

Boston Scientific Announces CE Mark Approval And First Implants Of Its Next-Generation X4 Quadripolar CRT-D Systems - Dec 17, 2013

Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4, DYNAGEN™ X4, and INOGEN™ X4...

Read more

Boston Scientific Completes Acquisition Of Bard Electrophysiology - Nov 01, 2013

Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard, Inc. The...

Read more

New Data Published In EP EuroPace Journal Highlights Differences In CRT-ICD Battery Longevity Across Manufacturers - Oct 08, 2013

University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity...

Read more

Boston Scientific To Acquire C.R. Bard Electrophysiology Business - Jun 28, 2013

In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation (NYSE:BSX) has entered into a...

Read more

First Implant Of Boston Scientific VITALIO™ Pacemaker Takes Place In Europe - Jun 26, 2013

The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIO™ pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition to a...

Read more

New Boston Scientific Pacemaker Family Features Technology For Adapting Pacing To Respiration - Jun 25, 2013

Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and support insight into...

Read more

New Analysis Suggests Lower Electrode-Related Complication Rate for Boston Scientific S-ICD® System Versus Transvenous ICD Leads - Jun 24, 2013

The Boston Scientific Corporation (NYSE:BSX) S-ICD™ (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related complications...

Read more

Data From More Than 100,000 Boston Scientific Implantable Defibrillators Show Battery Longevity Projections Of Nine To 13 Years - May 10, 2013

New data from 100,438 patients with Boston Scientific Corporation (NYSE:BSX) implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds)...

Read more

Boston Scientific Receives CE Mark Approval For The Rhythmia™ Mapping System - May 10, 2013

Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation solution for use in cardiac catheter...

Read more

Boston Scientific Completes First-In-Human Clinical Trial of the IntellaTip MiFi™ XP Ablation Catheter For Patients With Type 1 Atrial Flutter - May 06, 2013

Boston Scientific Corporation (NYSE: BSX) completed a first-in-human clinical trial utilizing the IntellaTip MiFi? XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia...

Read more

First Patient Treated In The Boston Scientific ZERO AF Clinical Trial To Evaluate The Safety And Performance Of The Blazer® Open-Irrigated Temperature Ablation Catheter - Jan 16, 2013

The first patient has been treated in the Boston Scientific Corporation (NYSE: BSX) ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer® Open-Irrigated...

Read more

Media Contacts

Rosie Ireland
Corporate Communications
+44 7585403359

Company Profile